Harmful infectious organisms are identified as invaders due to their antigens (distinct molecules on their surface). Each antibody produced by your immune system binds to a specific antigen and then ...

Naturally, the pharma industry has seen an explosion of mAbs in the pipeline, which has led to the evolution of new methods for improving and refining the antibody pipeline. Artificial ...

In the rapidly evolving field of antibody drug discovery, the ability to efficiently characterize and screen antibodies and antibody drug conjugates (ADCs) is crucial for developing effective ...

Combined clinical-stage company benefits from a strong pipeline: MOv18 IgE, an anti-Folate Receptorα IgE antibody, currently in a Phase Ib Proof of Concept trial in platinum-resistant ovarian cancer.

Epsilogen rose to prominence a few years ago by becoming the first biotech to start clinical testing of an antibody therapy for cancer based on immunoglobulin E (IgE), a departure from most ...

The anti-CCP antibody results correlated with RF, but were better than RF as predictor of a more aggressive disease course. After 3 years 5/97 patients had changed anti-CCP status: 2 from negative to ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...

But promising results from a recent clinical trial suggest that broadly neutralizing antibody therapy (bNAbs) may be able to accomplish the next best thing. Data from the trial—a collaboration ...

Epsilogen and TigaTx have not disclosed the financial terms of the deal. Credit: RealPeopleGroup via Getty Images. UK biotech Epsilogen has acquired US-based antibody developer TigaTx in a deal that ...

This study evaluated the effects of an extended dose interval on development of antibody and cell-mediated responses following the primary dose series and a subsequent booster dose. Methods: Blood ...

Dr. James Hansen, a Yale Cancer Center researcher, and his team discovered that using an antibody related to lupus they can breach the tumor and trigger an immune response to fight it. He says ...